Search Within

Ezra Y Rosen

Formats
  1. Meeting Abstract (27)
  2. Journal Article (19)
  3. Editorial (1)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Department of Medicine (49)
  2. Early Drug Development Service (49)
  3. Solid Tumor Oncology Division (49)
  4. Weinberg Fellows (49)
  5. GSK Faculty (26)
  6. Department of Pathology and Laboratory Medicine (25)

More Groups

People
  1. Alexander Drilon (22)
  2. Alison Schram (12)
  3. Marc Ladanyi (11)
  4. David Hyman (10)
  5. Mark Donoghue (9)
  6. Michael Berger (9)

More People

Years
  1. 2025 (1)
  2. 2024 (11)
  3. 2023 (10)
  4. 2022 (13)
  5. 2021 (4)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Annals of Oncology (9)
  3. Clinical Cancer Research (7)
  4. Cancer Research (4)
  5. JCO Precision Oncology (2)
  6. JNCI: Journal of the National Cancer Institute (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. American Association for Cancer Research (12)
  3. Oxford University Press (11)
  4. Nature Publishing Group (4)
  5. Elsevier Inc. (2)
  6. American Medical Association (1)

More Publishers

Results (49)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The cold immunological landscape of ATM-deficient cancers
    Journal Article

    Sinha, S.; Ng, V.; Novaj, A.; Zhu, Y.; Yazaki, S.; Pei, X.; Derakhshan, F.; Pareja, F.; Setton, J.; Naulin, F.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
    Meeting Abstract

    Carneiro, B. A.; Rosen, E.; Fontana, E.; Lee, E. K.; Mettu, N. B.; Lheureux, S.; Plummer, R.; Silverman, I. M.; Schonhoft, J. D.; Yang, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
    Meeting Abstract

    Vieito, M.; McKean, M.; Spira, A. I.; Rosen, E.; Rodon, J.; Garcia, V. M.; Gambardella, V.; Saavedra, O.; Cousin, S.; Cassier, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER plus metastatic breast cancer
    Meeting Abstract

    Rosen, E.; Caswell-Jin, J.; Berz, D.; Mai, N.; Fulgar, G.; Densel, M.; Chiang, G.; Sperry, S.; Warner, D.; Meric-Bernstam, F.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Genotypically-selected pan cancer trial of camonsertib with palliative radiation in the treatment of metastatic tumors harboring an ataxia-telangiectasia mutated (ATM) mutation
    Meeting Abstract

    Lee, N. Y.; Michelle, R.; Huang, M.; Guo, R.; Ferreira, V.; Merril, M.; Sgroe, E.; Unger, T.; Koehler, M.; Setton, J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Genotype-directed synthetic cytotoxicity of ATR inhibition with radiotherapy
    Journal Article

    Ng, V.; Sinha, S.; Novaj, A.; Ma, J.; McDermott, N.; Pei, X.; Longhini, A. L. F.; Grimsley, H.; Gardner, R.; Rosen, E.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
    Journal Article

    Fontana, E.; Rosen, E.; Lee, E. K.; Højgaard, M.; Mettu, N. B.; Lheureux, S.; Carneiro, B. A.; Cote, G. M.; Carter, L.; Plummer, R.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets
    Journal Article

    Chen, M. F.; Yang, S. R.; Tao, J. J.; Desilets, A.; Diamond, E. L.; Wilhelm, C.; Rosen, E.; Gong, Y.; Mullaney, K.; Torrisi, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma
    Meeting Abstract

    Gounder, M. M.; Rosen, E.; Parikh, A. R.; Conley, A. P.; Hong, D. S.; Sheth, S.; Mai, N.; Sgroe, E.; Mitchell, R.; Picard, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save